ArticleNeurourology and urodynamics2026
The Interpretability of the Neurogenic Bladder Symptom Score.
Article in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define mild, moderate and severe symptom categories of the neurogenic bladder symptom score (NBSS) and NBSS-short form (SF), and to calculate the minimal clinically important difference (MCID) of the NBSS-SF.
methodsWe used existing datasets from the original NBSS validation study (n = 230 patients with spinal cord injury (SCI), multiple sclerosis, and spina bifida), and a large cross-sectional study of people with SCI (n = 1479) who completed the NBSS. We used the previously validated mild-moderate-severe categories of the ICIQ-UI, IPSS, and the SCI-QOL Bladder complications scale to define patients with mild, moderate or severe symptoms, and mapped these to the NBSS scores for the related NBSS domains of incontinence, storage/voiding, and consequences, respectively. We validated these NBSS score categories using four data sets, and by examining the global bladder problem rating. An anchor-based MCID of the NBSS-SF was determined.
resultsUsing the median/interquartile range of the associated NBSS domain score of people who were in the moderate category of the ICIQ-UI, IPSS, and the SCI-QOL Bladder complications, we calculated the severity categories for the NBSS total score: 0-32 (mild), 33-48 (moderate), and 49-74 (severe). These score categories produced significantly different NBSS scores in 29/32 comparisons in four different study populations. The global bladder problem had good agreement with each domain's categorical scale. Finally, the group-level MCID of the NBSS-SF total score was calculated as an improvement of 1.8.
conclusionsWe have determined interpretability ranges for the NBSS and NBSS-SF. This can help interpret patient and clinical study results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.